Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome.

Cyclooxygenase 2 (COX-2) is an inflammation-associated enzyme involved in the pathogenesis of many solid tumors, but little is known about its presence and role in hematologic neoplasms. Multiple myeloma (MM) is known to involve a deregulated cytokine network with secretion of inflammatory mediators. We thus decided to investigate the involvement of COX-2 in this neoplasm. Western blotting (WB) was used to evaluate 142 bone marrow (BM) specimens, including MM and monoclonal gammopathy of undetermined significance (MGUS). Selected cases under-went further evaluation by WB on purified CD138(+) cells, immunohistochemistry (IC), and real-time polymerase chain reaction (PCR) for mRNA expression. COX-2 was expressed in 11% (2 of 18) of MGUS specimens, 31% (29 of 94) of MM at diagnosis, and 47% (14 of 30) of MM with relapsed/refractory disease. COX-2 positivity was associated with a poor outcome in terms of progression-free (18 vs 36 months; P < .001) and overall survival (28 vs 52 months; P < .05). Real-time PCR showed COX-2 mRNA overexpression. IC and cell separation studies demonstrated COX-2 expression to be restricted to malignant plasma cells. This is the first report of the presence and prognostic role of COX-2 expression in MM. Future studies will assess COX-2 involvement in other hematologic tumors and its potential use as a therapeutic or chemo-preventive target in onco-hematology.

[1]  K. Subbaramaiah,et al.  Thalidomide and its analogues inhibit lipopolysaccharide-mediated Iinduction of cyclooxygenase-2. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  M. Dohadwala,et al.  Autocrine/Paracrine Prostaglandin E2 Production by Non-small Cell Lung Cancer Cells Regulates Matrix Metalloproteinase-2 and CD44 in Cyclooxygenase-2-dependent Invasion* , 2002, The Journal of Biological Chemistry.

[3]  M. Hüll,et al.  Mechanisms of prostaglandin E2‐induced interleukin‐6 release in astrocytes: possible involvement of EP4‐like receptors, p38 mitogen‐activated protein kinase and protein kinase C , 2001, Journal of neurochemistry.

[4]  H. McKnight,et al.  Increased cyclooxygenase-2 (COX-2): a potential role in the pathogenesis of lymphoma. , 2004, Leukemia research.

[5]  R. Bolli,et al.  IL-6 plays an obligatory role in late preconditioning via JAK-STAT signaling and upregulation of iNOS and COX-2. , 2004, Cardiovascular research.

[6]  C. S. Lader,et al.  Prostaglandin E2, interleukin 1alpha, and tumor necrosis factor-alpha increase human osteoclast formation and bone resorption in vitro. , 1998, Endocrinology.

[7]  L. Milas,et al.  Initial Experience Combining Cyclooxygenase-2 Inhibition with Chemoradiation for Locally Advanced Pancreatic Cancer , 2003, American journal of clinical oncology.

[8]  J. Lewin,et al.  Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. , 2004, Cancer research.

[9]  W. Weichert,et al.  Elevated expression of cyclooxygenase‐2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma , 2003, Cancer.

[10]  S. Rivest,et al.  Effect of Acute Systemic Inflammatory Response and Cytokines on the Transcription of the Genes Encoding Cyclooxygenase Enzymes (COX‐1 and COX‐2) in the Rat Brain , 1998, Journal of neurochemistry.

[11]  S. Lippman,et al.  Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  N. Munshi,et al.  Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment. , 2002, Molecular cancer therapeutics.

[13]  P. L. Bergsagel,et al.  Advances in biology of multiple myeloma: clinical applications. , 2004, Blood.

[14]  Y. Mizutani,et al.  Enhanced sensitivity of bladder cancer cells to cisplatin mediated cytotoxicity and apoptosis in vitro and in vivo by the selective cyclooxygenase-2 inhibitor JTE-522. , 2004, The Journal of urology.

[15]  B. Barlogie,et al.  Antitumor activity of thalidomide in refractory multiple myeloma. , 1999, The New England journal of medicine.

[16]  J. Gera,et al.  Downstream effectors of oncogenic ras in multiple myeloma cells. , 2003, Blood.

[17]  C. Suh,et al.  Overexpression of cyclooxygenase‐2 is associated with a poor prognosis in patients with squamous cell carcinoma of the uterine cervix treated with radiation and concurrent chemotherapy , 2002, Cancer.

[18]  F. Watzinger,et al.  Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) – a Europe against cancer program , 2003, Leukemia.

[19]  C. la Vecchia,et al.  Fish consumption and cancer risk. , 1999, The American journal of clinical nutrition.

[20]  R. DuBois,et al.  Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors. , 1996, Gastroenterology.

[21]  P. Bergsagel,et al.  Critical roles for immunoglobulin translocations and cyclin D dysregulation in multiple myeloma , 2003, Immunological reviews.

[22]  H. Mizunuma,et al.  Clinical implication of expression of cyclooxygenase-2 and peroxisome proliferator activated-receptor γ in epithelial ovarian tumours , 2004, British Journal of Cancer.

[23]  B. Levin,et al.  The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. , 2000, The New England journal of medicine.

[24]  T. Hideshima,et al.  Molecular mechanisms of novel therapeutic approaches for multiple myeloma , 2002, Nature Reviews Cancer.

[25]  Bart Barlogie,et al.  A phase 2 study of bortezomib in relapsed, refractory myeloma. , 2003, The New England journal of medicine.

[26]  Sung-Chul Lim.  Role of COX-2, VEGF and cyclin D1 in mammary infiltrating duct carcinoma. , 2003, Oncology reports.

[27]  Bart Barlogie,et al.  Genetics and Cytogenetics of Multiple Myeloma , 2004, Cancer Research.

[28]  A. Tarnawski,et al.  Prostaglandin E2 transactivates EGF receptor: A novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy , 2002, Nature Medicine.

[29]  Yukihiko Sugimoto,et al.  Host Prostaglandin E 2-EP 3 Signaling Regulates Tumor-Associated Angiogenesis and Tumor Growth , 2003 .

[30]  B. Aggarwal,et al.  Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates activation of cigarette smoke-induced nuclear factor (NF)-kappaB by suppressing activation of IkappaBalpha kinase in human non-small cell lung carcinoma: correlation with suppression of cyclin D1, COX-2, and matrix metalloproteinase-9. , 2004, Cancer research.

[31]  T. Hanafusa,et al.  Vascular endothelial growth factor and interleukin 6 expression by Hodgkin/Reed‐Sternberg cells , 2004, British Journal of Haematology.

[32]  Yukihiko Sugimoto,et al.  Host Prostaglandin E2-EP3 Signaling Regulates Tumor-Associated Angiogenesis and Tumor Growth , 2003, The Journal of experimental medicine.

[33]  N. Hayashi,et al.  Inhibition of angiotensin II activity enhanced the antitumor effect of cyclooxygenase-2 inhibitors via insulin-like growth factor I receptor pathway. , 2003, Cancer research.

[34]  J. Masferrer,et al.  Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors. , 2002, Cancer research.

[35]  G. Morgan,et al.  Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. , 2003, The hematology journal : the official journal of the European Haematology Association.

[36]  M. Singer,et al.  BMI and waist circumference as predictors of lifetime colon cancer risk in Framingham Study adults , 2004, International Journal of Obesity.

[37]  Richard LeBlanc,et al.  Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. , 2002, Blood.

[38]  E. Mantzioris,et al.  Biochemical effects of a diet containing foods enriched with n-3 fatty acids. , 2000, The American journal of clinical nutrition.

[39]  M. Press,et al.  Body weight correlates with mortality in early-stage breast cancer. , 2004, Archives of surgery.

[40]  K. Anderson.  Moving disease biology from the lab to the clinic , 2003, Cancer.

[41]  H. Mayani,et al.  In vitro characterization of hematopoietic microenvironment cells from patients with myelodysplastic syndrome. , 2002, Leukemia research.

[42]  Steffen Hauptmann,et al.  Prognostic impact of cyclooxygenase-2 in breast cancer. , 2004, Clinical breast cancer.

[43]  P. Isakson,et al.  Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis. , 1996, The Journal of clinical investigation.

[44]  J. Masferrer,et al.  Synergy between Celecoxib and Radiotherapy Results from Inhibition of Cyclooxygenase-2-Derived Prostaglandin E2, a Survival Factor for Tumor and Associated Vasculature , 2004, Cancer Research.

[45]  H. Young,et al.  Angiogenic effects of prostaglandin E2 are mediated by up-regulation of CXCR4 on human microvascular endothelial cells. , 2003, Blood.

[46]  M. Peck,et al.  Role of prostaglandin-mediated vasodilatation in inflammation , 1977, Nature.

[47]  J. Palmblad,et al.  Expression of cox‐2, tie‐2 and glycodelin by megakaryocytes in patients with chronic myeloid leukaemia and polycythaemia vera , 2003, British journal of haematology.

[48]  R. Hayes,et al.  Diet and nutrition as risk factors for multiple myeloma among blacks and whites in the United States , 2001, Cancer Causes & Control.

[49]  M. Ergin,et al.  Cyclooxygenase-2 (Cox-2) Expression in Lymphomas , 2004, Leukemia & lymphoma.

[50]  C. Hudis,et al.  Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer. , 2002, Cancer research.

[51]  F. Zhan,et al.  Toward the identification of distinct molecular and clinical entities of multiple myeloma using global gene expression profiling. , 2003, Seminars in hematology.

[52]  S. Jagannath,et al.  CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION , 1998, British journal of haematology.

[53]  H. Kantarjian,et al.  Bone marrow cyclooxygenase‐2 levels are elevated in chronic‐phase chronic myeloid leukaemia and are associated with reduced survival , 2002, British journal of haematology.

[54]  E. Kliewer,et al.  Dietary fish intake and risk of leukaemia, multiple myeloma, and non-Hodgkin lymphoma. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[55]  B. Barlogie,et al.  Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization‐defined chromosome 13 deletion in multiple myeloma: early results of total therapy II , 2003, British journal of haematology.

[56]  M. Rigaud,et al.  Cyclooxygenase-2 expression in human adenocarcinoma cell line HT29 cl.19A. , 1998, Anticancer research.

[57]  B. Klein.  Cytokine, cytokine receptors, transduction signals, and oncogenes in human multiple myeloma. , 1995, Seminars in hematology.